To include your compound in the COVID-19 Resource Center, submit it here.

Xanelim anti-CD11a: Phase III

Pooled data from 1095 patients in 2 Phase III trials showed that

Read the full 120 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE